2016 American Transplant Congress
Targeting IFN-g-Expressing TIM-4+ B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.
1University of Pittsburgh, Pittsburgh; 2Harvard Medical School, Boston.
B cell depletion can augment or inhibit auto- and allo- immune responses in humans and mice without altering Ig levels. This is likely due to…2016 American Transplant Congress
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.
Induction therapy with depleting antibodies reduces rejection rate and potentially improves efficacy of steroid free regimens after renal transplantation.This prospective, single-centre, cohort study evaluated cumulative…2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…2016 American Transplant Congress
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.
Background: Rapamycin (RAPA), an immunosuppressive agent, inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and mTORC2). While…2016 American Transplant Congress
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.
Purpose: Acute rejection and poor graft function are two major risk factors for allograft failure in kidney transplant (KTx) recipients (KTxR). Although, graft survival and…2016 American Transplant Congress
An Epidemiological Update of Non-Melanoma Skin Cancer in Immunosuppressed Organ Transplant Recipients with Skin of Color.
Dermatology, Drexel University College of Medicine, Philadelphia, PA.
Introduction:It is predicted by the US census that by year 2050, minorities will become the majority US population. We know skin cancer in patients with…2016 American Transplant Congress
Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressants is associated with rejection and graft loss and nonadherence to antidiabetics is associated with poor glycaemic control leading to microvascular complications and…2016 American Transplant Congress
Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.
Tremor is a common side effect of tacrolimus (tac) correlated with peak-dose drug concentration. Envarsus XR®, a novel, once-daily, extended-release formulation of tac, has a…2016 American Transplant Congress
What if Mycophenolic Acid Product Is Discontinued Less Than 6 Weeks Before Pregnancy?
It is recommended that mycophenolic acid (MPA) products be discontinued at least 6 wks prior to conceiving due to potential teratogenic effects and increase risk…
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 138
- Next Page »